PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17022864-6 2006 Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p < 0.001), non-high-density lipoprotein cholesterol (p < 0.001), lipid ratios (p < or = 0.003), and apolipoprotein B (p < 0.05). Simvastatin 10-21 apolipoprotein B Homo sapiens 201-217 16545796-5 2006 Furthermore, both EP2300 compounds and simvastatin significantly reduced triglyceride synthesis and apoB secretion and increased LDL receptor expression and LDL uptake in HepG2 cells. Simvastatin 39-50 apolipoprotein B Homo sapiens 100-104 16005883-4 2006 Atorvastatin and simvastatin reduced plasma-oxidized LDL (-43 and -35%, respectively) in proportion to the decrease in plasma apolipoprotein B. Simvastatin 17-28 apolipoprotein B Homo sapiens 126-142 12686335-10 2003 Simvastatin therapy decreased total cholesterol by 27%, non-HDL cholesterol by 30%, total apolipoprotein B by 31%, very low-density lipoprotein (VLDL) + intermediate-density lipoprotein (IDL) cholesterol by 37%, VLDL + IDL apolipoprotein B by 14%, LDL cholesterol by 28%, and LDL apolipoprotein B by 21%. Simvastatin 0-11 apolipoprotein B Homo sapiens 90-106 16162940-0 2005 Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. Simvastatin 25-36 apolipoprotein B Homo sapiens 58-74 16162940-3 2005 Simvastatin therapy decreased TG, cholesterol, and apoB significantly in VLDL, IDL, and LDL. Simvastatin 0-11 apolipoprotein B Homo sapiens 51-55 15642080-10 2005 Ezetimibe plus simvastatin 20 mg also produced significant incremental reductions in non-HDL-C (p < 0.001), very low-density lipoprotein cholesterol (p < 0.05) and apolipoprotein B (p < 0.001) relative to simvastatin 40 mg. Simvastatin 15-26 apolipoprotein B Homo sapiens 170-186 15265253-4 2004 RESULTS: Both simvastatin 80 and 40 mg significantly increased total HDL-C from baseline (mean increases of 8% +/- 1 [SE] and 5% +/- 1, respectively; p < 0.001) compared with placebo, and significantly reduced plasma concentrations of LDL-C (p < 0.001), triglycerides (p < 0.001), apolipoprotein B (p < 0.001), and hs-CRP (p < or = 0.012). Simvastatin 14-25 apolipoprotein B Homo sapiens 290-306 15132403-8 2004 Treatment with ezetimibe/simvastatin also led to greater reductions in total cholesterol, triglyceride, non-high-density lipoprotein cholesterol, and apolipoprotein B levels compared with simvastatin alone; both treatments increased high-density lipoprotein cholesterol levels similarly. Simvastatin 25-36 apolipoprotein B Homo sapiens 150-166 15110130-12 2004 Simvastatin produced significant reductions in concentrations of total cholesterol, triglycerides (TG), non-high-density lipoprotein cholesterol, and apolipoprotein (apo) B compared with placebo (all, P<0.001 ) and significant increases in concentrations of high-density lipoprotein cholesterol (HDL-C) ( P=0.002 ) and apo A-I ( P=0.006 ). Simvastatin 0-11 apolipoprotein B Homo sapiens 150-172 12686335-10 2003 Simvastatin therapy decreased total cholesterol by 27%, non-HDL cholesterol by 30%, total apolipoprotein B by 31%, very low-density lipoprotein (VLDL) + intermediate-density lipoprotein (IDL) cholesterol by 37%, VLDL + IDL apolipoprotein B by 14%, LDL cholesterol by 28%, and LDL apolipoprotein B by 21%. Simvastatin 0-11 apolipoprotein B Homo sapiens 223-239 12686335-10 2003 Simvastatin therapy decreased total cholesterol by 27%, non-HDL cholesterol by 30%, total apolipoprotein B by 31%, very low-density lipoprotein (VLDL) + intermediate-density lipoprotein (IDL) cholesterol by 37%, VLDL + IDL apolipoprotein B by 14%, LDL cholesterol by 28%, and LDL apolipoprotein B by 21%. Simvastatin 0-11 apolipoprotein B Homo sapiens 223-239 12404199-9 2002 Apolipoprotein (Apo) B was decreased by simvastatin (-25%, P <.001) and by CEE (-10%, P <.05); again, simvastatin was more effective than either diet or ETP. Simvastatin 40-51 apolipoprotein B Homo sapiens 0-22 12901521-0 2003 The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Simvastatin 78-89 apolipoprotein B Homo sapiens 17-33 12901521-12 2003 CONCLUSION: The relative frequency of apoB X+ allele is high in patients with hyperlipidemia, in whom the TC-lowering efficacy is decreased following treatment of simvastatin. Simvastatin 163-174 apolipoprotein B Homo sapiens 38-42 12404199-9 2002 Apolipoprotein (Apo) B was decreased by simvastatin (-25%, P <.001) and by CEE (-10%, P <.05); again, simvastatin was more effective than either diet or ETP. Simvastatin 108-119 apolipoprotein B Homo sapiens 0-22 10217372-3 1999 Simvastatin, unlike placebo, reduced the lipid and apolipoprotein B contents of the most abundant LDL-1, LDL-2, and LDL-3 subfractions without inducing significant changes in the overall size distribution of LDL and HDL. Simvastatin 0-11 apolipoprotein B Homo sapiens 51-67 12390953-6 2002 After 48 weeks of simvastatin therapy, there were significant reductions of LDL cholesterol (-41%), total cholesterol (-31%), apolipoprotein B (-34%), VLDL cholesterol (-21%), and triglyceride (-9%) levels. Simvastatin 18-29 apolipoprotein B Homo sapiens 126-142 12390953-10 2002 CONCLUSIONS: Simvastatin significantly reduced LDL cholesterol, total cholesterol, triglyceride, VLDL cholesterol, and apolipoprotein B levels and was well tolerated in children with heFH. Simvastatin 13-24 apolipoprotein B Homo sapiens 119-135 12119202-0 2002 Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Simvastatin 30-41 apolipoprotein B Homo sapiens 45-61 12119202-1 2002 Subjects with moderate combined hyperlipidemia (n=11) were assessed in an investigation of the effects of atorvastatin and simvastatin (both 40 mg per day) on apolipoprotein B (apoB) metabolism. Simvastatin 123-134 apolipoprotein B Homo sapiens 159-175 12119202-6 2002 Both drugs stimulated direct catabolism of large very low density lipoprotein (VLDL(1)) apoB (4.52+/-3.06 pools per day on atorvastatin; 5.48+/-4.76 pools per day on simvastatin versus 2.26+/-1.65 pools per day at baseline (both P<0.05)) and this was the basis of the 50% reduction in plasma VLDL(1) concentration; apoB production in this fraction was not significantly altered. Simvastatin 166-177 apolipoprotein B Homo sapiens 88-92 12119202-8 2002 IDL apoB direct catabolism rose from 0.54+/-0.30 pools per day at baseline to 1.17+/-0.87 pools per day on atorvastatin and to 0.95+/-0.43 pools per day on simvastatin (both P<0.05). Simvastatin 156-167 apolipoprotein B Homo sapiens 4-8 12119202-9 2002 Similarly the fractional transfer rate for IDL to LDL conversion was enhanced 58-84% by statin treatment (P<0.01) LDL apoB fractional catabolic rate (FCR) which was low at baseline in these subjects (0.22+/-0.04 pools per day) increased to 0.44+/-0.11 pools per day on atorvastatin and 0.38+/-0.11 pools per day on simvastatin (both P<0.01). Simvastatin 318-329 apolipoprotein B Homo sapiens 121-125 12119202-13 2002 We conclude that in patients with moderate combined hyperlipidemia who initially have a low FCR for VLDL and LDL apoB, the principal action of atorvastatin and simvastatin is to stimulate receptor-mediated catabolism across the spectrum of apoB-containing lipoproteins. Simvastatin 160-171 apolipoprotein B Homo sapiens 113-117 12119202-13 2002 We conclude that in patients with moderate combined hyperlipidemia who initially have a low FCR for VLDL and LDL apoB, the principal action of atorvastatin and simvastatin is to stimulate receptor-mediated catabolism across the spectrum of apoB-containing lipoproteins. Simvastatin 160-171 apolipoprotein B Homo sapiens 240-244 12153549-2 2002 We now investigate the effect of an HMG-CoA reductase inhibitor (simvastatin) on chylomicron remnant metabolism using the measurement of fasting apoB-48 and RLP-C in FH patients after long- and short-term simvastatin therapy and after a wash-out period. Simvastatin 65-76 apolipoprotein B Homo sapiens 145-152 12153549-7 2002 RESULTS: Both long- and short-term treatment with simvastatin were associated with decreases in the plasma concentration of apoB-48 (P < 0.05) and RLP-C (P < 0.001), but there was no significant change in the FCR of the emulsion. Simvastatin 50-61 apolipoprotein B Homo sapiens 124-131 12153549-8 2002 CONCLUSIONS: We suggest that long- and short-term treatments with simvastatin have comparable effects in decreasing the plasma concentration of triglyceride-rich remnants in heterozygous FH, as measured by fasting apoB-48 and RLP-C. Simvastatin 66-77 apolipoprotein B Homo sapiens 214-221 11427209-9 2001 Simvastatin also induced treatment- and time-dependent reductions in apo B-100, whereas the MTP inhibitor BMS-201038 exhibited no time dependency, instead inhibiting this variable even on 1-h treatment. Simvastatin 0-11 apolipoprotein B Homo sapiens 69-78 10617243-9 1999 RESULTS: Compared to placebo, 5 mg simvastatin/d significantly decreased total cholesterol by 20% (p < 0.01), low-density lipoprotein cholesterol (LDL cholesterol) by 29% (p < 0.01), and Apolipoprotein B (ApoB) by 26% (p < 0.01). Simvastatin 35-46 apolipoprotein B Homo sapiens 193-209 10617243-9 1999 RESULTS: Compared to placebo, 5 mg simvastatin/d significantly decreased total cholesterol by 20% (p < 0.01), low-density lipoprotein cholesterol (LDL cholesterol) by 29% (p < 0.01), and Apolipoprotein B (ApoB) by 26% (p < 0.01). Simvastatin 35-46 apolipoprotein B Homo sapiens 211-215 10525131-4 1999 After 10-20 months on biweekly LA combined with simvastatin 40 mg per day immediate pre-apheresis levels of TC, LDL-cholesterol, and apolipoprotein B were decreased to 5.3+/-1.3 mmol/l, 3.3+/-1.2 mmol/l, and 1.6+/-0.4 g/l, respectively, whereas apheresis induced mean acute reductions of 61, 78, and 76%, respectively. Simvastatin 48-59 apolipoprotein B Homo sapiens 133-149 10563066-10 1999 Mean fasting apolipoprotein A1 and lipoprotein A1 were increased and apolipoprotein B decreased by cerivastatin and simvastatin therapy. Simvastatin 116-127 apolipoprotein B Homo sapiens 69-85 11902822-12 2001 CONCLUSIONS: In patients on long-term simvastatin treatment, ACTH had marked lowering effects on the lipoproteins that contain apolipoprotein B. Simvastatin 38-49 apolipoprotein B Homo sapiens 127-143 10357840-0 1999 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. Simvastatin 125-136 apolipoprotein B Homo sapiens 27-43 9809932-10 1998 Apolipoprotein B was significantly reduced by simvastatin, alone and combined with HRT, by 39% and 35%, respectively, compared to placebo (p < 0.001). Simvastatin 46-57 apolipoprotein B Homo sapiens 0-16 10432174-3 1999 Fasting plasma total and LDL cholesterol and apolipoprotein B (apo B) were significantly lower on simvastatin compared to placebo. Simvastatin 98-109 apolipoprotein B Homo sapiens 45-61 9316434-1 1997 We examined the effect of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the kinetics of very low-density lipoprotein apolipoprotein B-100 (VLDL apoB) in 13 normolipidemic men in a placebo-controlled crossover study. Simvastatin 26-37 apolipoprotein B Homo sapiens 152-172 18370543-9 1998 Apolipoprotein B was reduced by both drugs (-33%, p < 0.001 for atorvastatin and -18%, p < 0.05 for simvastatin), but plasma fibrinogen and triglyceride were reduced only by atorvastatin (-20%, p < 0.01; -36%, p < 0.001, respectively). Simvastatin 106-117 apolipoprotein B Homo sapiens 0-16 9576425-4 1998 The reduction in MCEs within the simvastatin group was highly correlated with on-treatment levels and changes from baseline in total and LDL cholesterol, apolipoprotein B, and less so with HDL cholesterol, but there was no clear relationship with triglycerides. Simvastatin 33-44 apolipoprotein B Homo sapiens 154-170 9316434-4 1997 Simvastatin decreased VLDL apoB pool size by 53% and the hepatic secretion rate of VLDL apoB by 46% but did not significantly alter its fractional catabolism. Simvastatin 0-11 apolipoprotein B Homo sapiens 27-31 8842455-8 1996 Statins reduced the apo B100 level secreted by the two cell types (simvastatin) or human hepatocytes (crilvastatin). Simvastatin 67-78 apolipoprotein B Homo sapiens 20-28 9476046-0 1997 Simvastatin reduces activation of normal platelets by LDL isolated from patients with familial hypercholesterolaemia and familial defective apolipoprotein B. Simvastatin 0-11 apolipoprotein B Homo sapiens 140-156 9241623-8 1997 Among the patients assigned simvastatin, total cholesterol was reduced by 13% (2p = 0.001), LDL cholesterol was reduced by 17% (2p = 0.003) and apolipoprotein B was reduced by 12% (2p = 0.005) compared to patients assigned placebo. Simvastatin 28-39 apolipoprotein B Homo sapiens 144-160 9027779-5 1997 RESULTS: Simvastatin therapy significantly reduced serum cholesterol, LDL cholesterol, apoB concentrations, and both NCET (P = 0.001) and LCAT (P = 0.012) rates. Simvastatin 9-20 apolipoprotein B Homo sapiens 87-91 9027779-7 1997 CONCLUSIONS: These data show that simvastatin therapy reduces serum NCET rates, and suggest that this may be linked to the concomitant decrease in levels of apoB-containing lipoproteins which are acceptors of transferred cholesteryl esters, and to the decrease in serum LCAT rates in patients with chronic renal failure with treatment. Simvastatin 34-45 apolipoprotein B Homo sapiens 157-161 7749833-6 1995 The reduction in 11-dehydro-TXB2 associated with simvastatin was correlated with the reduction in total cholesterol (r = .81, P < .0001), LDL cholesterol (r = .79, P < .0001), and apolipoprotein B (r = .76, P < .0001) levels. Simvastatin 49-60 apolipoprotein B Homo sapiens 186-202 8620338-0 1996 Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Simvastatin 52-63 apolipoprotein B Homo sapiens 67-83 7589011-5 1995 We conclude that the hepatic secretion of VLDL apoB in FH is decreased by simvastatin, which may partly explain the fall in plasma cholesterol. Simvastatin 74-85 apolipoprotein B Homo sapiens 47-51 7578166-7 1995 Apolipoprotein B levels were reduced by 29% at the end of 1 year with simvastatin but not with the other treatments. Simvastatin 70-81 apolipoprotein B Homo sapiens 0-16 7585842-3 1995 Simvastatin caused significant decreases of total cholesterol (-18.1%), LDL cholesterol (-27.6%), and apolipoprotein B (-21.8%), and significantly reduced total cholesterol, free cholesterol, cholesterol esters, phospholipids, and protein in LDL without significantly changing the component ratios and fatty acid levels of LDL. Simvastatin 0-11 apolipoprotein B Homo sapiens 102-118 8243858-2 1993 In a double-blind, randomized and placebo-controlled design treatment with simvastatin (n = 8) for 36 weeks significantly reduced total cholesterol (6.7 +/- 0.3 vs 5.1 mmol.l-1 (p < 0.01)), LDL-cholesterol (4.4 +/- 0.3 vs 2.9 +/- 0.2 mmol.l-1 (p < 0.01)) and apolipoprotein B (1.05 +/- 0.04 vs 0.77 +/- 0.02 mmol.l-1 (p < 0.01)) levels as compared to placebo (n = 10). Simvastatin 75-86 apolipoprotein B Homo sapiens 265-281 8187355-4 1994 Treatment with simvastatin in increasing doses over a period of three months (13 patients received 40 mg/day and 5 patients 20 mg/day at the end of the third month) reduced LDL-cholesterol in both groups of patients (35% and 54%) as well as apolipoprotein B (apoB) (31% and 46%) significantly, but Lp(a) levels were not influenced (57 +/- 21 vs 59 +/- 20 and 50 +/- 14 vs 53 +/- 16 mg/dl, respectively). Simvastatin 15-26 apolipoprotein B Homo sapiens 241-257 8187355-4 1994 Treatment with simvastatin in increasing doses over a period of three months (13 patients received 40 mg/day and 5 patients 20 mg/day at the end of the third month) reduced LDL-cholesterol in both groups of patients (35% and 54%) as well as apolipoprotein B (apoB) (31% and 46%) significantly, but Lp(a) levels were not influenced (57 +/- 21 vs 59 +/- 20 and 50 +/- 14 vs 53 +/- 16 mg/dl, respectively). Simvastatin 15-26 apolipoprotein B Homo sapiens 259-263 8264145-7 1993 Apolipoprotein B100 levels fell by a mean of 31% in the simvastatin group but rose 0.3% in the placebo group (P = 0.014). Simvastatin 56-67 apolipoprotein B Homo sapiens 0-19 1627634-6 1992 Apo-B concentration in the medium of Hep G2 cells was 31% lower after 31 h incubation with simvastatin than in controls. Simvastatin 91-102 apolipoprotein B Homo sapiens 0-5 8240151-8 1993 RESULTS: Over the 18 week direct comparison of the two drugs, there was a significant difference (p < 0.001) in response between simvastatin and pravastatin for reduction in levels of total cholesterol (32% vs 21% respectively), LDL cholesterol (38% vs 27%) and apolipoprotein B levels (34% vs 23%). Simvastatin 132-143 apolipoprotein B Homo sapiens 265-281 8240151-11 1993 When pravastatin was replaced with simvastatin for the final 6 weeks of the study in the 23 patients initially randomised to pravastatin, there were further reductions (p < 0.01) in total and LDL cholesterol, and apolipoprotein B. Simvastatin 35-46 apolipoprotein B Homo sapiens 216-232 8326293-13 1993 CONCLUSIONS: Simvastatin appeared to be more potent than pravastatin in lowering total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B, whereas both drugs had the same short-term safety profile. Simvastatin 13-24 apolipoprotein B Homo sapiens 140-156 8487674-3 1993 Treatment with simvastatin reduced plasma cholesterol level by 16% (mean +/- SEM, 8.1 +/- 0.8 v 6.8 +/- 0.8 mmol/L; P < .05) and plasma apolipoprotein (apo) B level by 19% (1.6 +/- 0.2 v 1.3 +/- 0.2 g/L; P < .05). Simvastatin 15-26 apolipoprotein B Homo sapiens 139-161 8427854-0 1993 Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Simvastatin 11-22 apolipoprotein B Homo sapiens 26-30 8122478-3 1993 Simvastatin was found to produce significantly greater mean percent reductions from baseline in total cholesterol (28% versus 21%), LDL cholesterol (38% versus 29%), and apolipoprotein B concentrations (25% versus 17%) than did pravastatin, and a greater percentage of patients receiving simvastatin (94% versus 80%) had at least a 20% reduction in LDL cholesterol. Simvastatin 0-11 apolipoprotein B Homo sapiens 170-186 8122478-5 1993 Resulting reductions in the ratios of total cholesterol: HDL cholesterol, LDL cholesterol: HDL cholesterol, and apolipoprotein B: apolipoprotein A-I were significantly greater in the simvastatin group. Simvastatin 183-194 apolipoprotein B Homo sapiens 112-128 1495661-4 1992 Apo-B was also significantly lower on 40 mg simvastatin (p less than 0.01). Simvastatin 44-55 apolipoprotein B Homo sapiens 0-5 1352930-7 1992 As expected, simvastatin produced a significant reduction in serum levels of total cholesterol (33 +/- 12 and 36 +/- 12 percent, mean +/- SD, after 4 and 8 weeks respectively, p less than 0.001 vs baseline), LDL-cholesterol (36 +/- 5 and 43 +/- 6 percent respectively, p less than 0.001 vs baseline) and apolipoprotein-B (20 +/- 29 and 23 +/- 30 percent respectively, p less than 0.05 vs baseline), whereas these parameters did not change significantly in the placebo group. Simvastatin 13-24 apolipoprotein B Homo sapiens 304-320 1320552-7 1992 Simvastatin produced consistent reductions in total plasma cholesterol concentration (median 36.9%), plasma low-density lipoprotein-cholesterol concentration (43.6%) and apolipoprotein B pool size (29.9%). Simvastatin 0-11 apolipoprotein B Homo sapiens 170-186 1436290-3 1992 Simvastatin reduced total serum cholesterol (300.0 +/- 15.5 vs. 193.0 +/- 8.0; -35%), LDL cholesterol (203.8 +/- 13.0 vs. 104.7 +/- 6.0; -48.0%) as well as apolipoprotein B (132.3 +/- 6.6 vs. 77.8 +/- 2.7 mg/dl; -40%). Simvastatin 0-11 apolipoprotein B Homo sapiens 156-172 2312032-3 1990 Simvastatin 40 mg decreased total serum cholesterol, LDL cholesterol and apolipoprotein B by 35%, 40% and 35%, respectively, while HDL cholesterol and apolipoprotein A-I increased by 10% (p less than 0.01) and 7% (p less than 0.05), respectively. Simvastatin 0-11 apolipoprotein B Homo sapiens 73-89 1789814-6 1991 Simvastatin had a more pronounced effect than fenofibrate on apolipoprotein B. Simvastatin 0-11 apolipoprotein B Homo sapiens 61-77 2051734-4 1991 Lovastatin (1st month 20 mg; 2nd and 3rd months 40 mg day-1) and simvastatin (1st month 10 mg, 2nd month 20 mg and 3rd month 40 mg day-1) reduced total serum cholesterol from 280.3 +/- 9.4 to 213.0 +/- 6.7 (-24%) and 295.0 +/- 12.2 to 202.3 +/- 8.9 mg/dl (-31.4%), LDL cholesterol from 161.9 +/- 10.7 to 112.1 +/- 7.9 (-30.8%) and 181.8 +/- 14.7 to 107.4 +/- 8.1 mg/dl (-40.9%), as well as apolipoprotein B (apo B) from 116.0 +/- 6.6 to 83.3 +/- 3.7 (-28.2%) and 134.4 +/- 8.2 to 84.1 +/- 5.3 mg/dl (-37.4%), respectively. Simvastatin 65-76 apolipoprotein B Homo sapiens 390-406 2054273-2 1991 Total serum cholesterol, LDL-cholesterol and apoprotein B (ApoB) were significantly reduced by simvastatin 40 mg daily. Simvastatin 95-106 apolipoprotein B Homo sapiens 45-57 2054273-2 1991 Total serum cholesterol, LDL-cholesterol and apoprotein B (ApoB) were significantly reduced by simvastatin 40 mg daily. Simvastatin 95-106 apolipoprotein B Homo sapiens 59-63 1987991-3 1991 With simvastatin treatment, the mean decreases in total cholesterol, low density lipoprotein (LDL) cholesterol, and apolipoprotein B (apo B) were 39%, 46%, and 36%, respectively. Simvastatin 5-16 apolipoprotein B Homo sapiens 116-132 1777975-2 1991 Under simvastatin therapy the concentrations of total cholesterol, total triglyceride, very low density lipoprotein cholesterol and triglyceride, low density lipoprotein cholesterol and apolipoprotein B in serum fell significantly by 30%, 30%, 43%, 28%, 36% and 26%, respectively, and the concentration of high density lipoprotein cholesterol rose significantly by 14%. Simvastatin 6-17 apolipoprotein B Homo sapiens 186-202 1671145-0 1991 Poor response to simvastatin in familial defective apo-B-100. Simvastatin 17-28 apolipoprotein B Homo sapiens 51-60 2073672-11 1990 Simvastatin significantly reduces TC, LDL, and apolipoprotein (apo) B (30%, 35%, and 27%, respectively). Simvastatin 0-11 apolipoprotein B Homo sapiens 47-69 2634479-6 1989 Long-term simvastatin treatment was well tolerated (lack of important side effects as well as of significant changes of other clinical and laboratory parameters) and effective, reducing significantly (p less than 0.01) TC (317.9 +/- 30.8 vs 238.5 +/- 37.9 mg/dl), LDLc (210.6 +/- 48 vs 147.9 +/- 52 mg/dl), ApoB (144.7 +/- 17.5 vs 104.5 +/- 18), and TG (272.9 +/- 184 vs 200.5 +/- 117.6 mg/dl) and increasing in contrast HDL and ApoA values. Simvastatin 10-21 apolipoprotein B Homo sapiens 307-311 2904053-5 1988 With simvastatin the apolipoprotein B level decreased by 30%, whereas the apolipoprotein A level increased by 10%. Simvastatin 5-16 apolipoprotein B Homo sapiens 21-37 2736571-10 1989 These data indicate that simvastatin, even at a low dose of 2.5 to 5 mg daily, causes consistent reductions in serum TC, LDL-C, apo B, and TG, and a rise in HDL-C and antiatherogenic lipoproteins. Simvastatin 25-36 apolipoprotein B Homo sapiens 128-133 2502417-7 1989 Simvastatin and cholestyramine reduced the mean plasma apolipoprotein B concentration by 28% and 13%, respectively. Simvastatin 0-11 apolipoprotein B Homo sapiens 55-71 20413733-4 2010 LDLR haplotype 5 (LDLR L5) was associated with smaller simvastatin-induced reductions in low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B (P=0.0002 to 0.03) in blacks but not whites. Simvastatin 55-66 apolipoprotein B Homo sapiens 191-207 3234467-4 1988 Serum apolipoprotein B fell by 33.3% (simvastatin) and 15.7% (bezafibrate). Simvastatin 38-49 apolipoprotein B Homo sapiens 6-22 31969989-4 2020 Across phenotypes of statin-induced LDL-C change, baseline adjustment identified variants from six loci meeting genome-wide significance (SORT/CELSR2/PSRC1, LPA, SLCO1B1, APOE, APOB, and SMARCA4/LDLR). Simvastatin 21-27 apolipoprotein B Homo sapiens 177-181 24092915-10 2013 The elevation in apoB-containing lipoproteins in hypercholesterolemic patients is mainly attributed to the relative increase in the proatherogenic apoB/Lp-PLA2, while simvastatin reduces these particles to a higher extent compared with apoB/Lp-PLA2-. Simvastatin 167-178 apolipoprotein B Homo sapiens 17-21 23890516-0 2013 Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Simvastatin 216-227 apolipoprotein B Homo sapiens 176-192 23166513-6 2012 Furthermore, inter-individual variation in statin-induced RHOA mRNA expression measured in vitro in CAP LCLs was correlated with the changes in plasma total cholesterol, LDL-cholesterol, and APOB induced by simvastatin treatment (40 mg/d for 6 wk) of the individuals from whom these cell lines were derived. Simvastatin 207-218 apolipoprotein B Homo sapiens 191-195 20345493-5 2011 There was a statistically significant decrease in total cholesterol, triglycerides, low-density lipoprotein cholesterol, and apolipoprotein-B levels as well as in the apolipoprotein-B/apolipoprotein-A1 index after a 1-month therapy with 40 mg simvastatin (P <0.001). Simvastatin 243-254 apolipoprotein B Homo sapiens 167-183 21859750-5 2011 Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). Simvastatin 25-36 apolipoprotein B Homo sapiens 203-219 21029821-6 2010 Improvements in non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and lipoprotein ratios were significantly greater with ezetimibe/simvastatin than atorvastatin for all comparisons (p <0.01 to <0.001). Simvastatin 160-171 apolipoprotein B Homo sapiens 77-93 2894548-2 1988 Simvastatin was better than bezafibrate at lowering total and low-density lipoprotein (LDL)-cholesterol and apolipoprotein B concentrations (30.4% [p less than 0.001], 37.3% [p less than 0.001], and 37.8% [p less than 0.001] vs 17.0%, 19.6%, and 24.0%, respectively). Simvastatin 0-11 apolipoprotein B Homo sapiens 108-124 2894548-7 1988 The results show that simvastatin was more effective than bezafibrate in lowering total-cholesterol, LDL-cholesterol, and apolipoprotein B, while bezafibrate was better at lowering triglycerides and VLDL-cholesterol and at raising HDL-cholesterol and apolipoprotein A-I. Simvastatin 22-33 apolipoprotein B Homo sapiens 122-138 26336957-5 2015 Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Simvastatin 10-21 apolipoprotein B Homo sapiens 91-107 24855368-7 2014 CONCLUSION: Greater dissociation of apoB, LDL-C, and non-HDL-C targets occur following treatment with ERN/LRPT, SIMVA, and ERN/LRPT + SIMVA in patients with dyslipidemia. Simvastatin 112-117 apolipoprotein B Homo sapiens 36-40 24092915-6 2013 The plasma apoB/Lp-PLA2 concentration in 50 normolipidemic controls and 53 patients with primary hypercholesterolemia at baseline and at 3 months posttreatment with simvastatin (40 mg/day) was determined by an enzyme-linked immunosorbent assay. Simvastatin 165-176 apolipoprotein B Homo sapiens 11-15 24092915-9 2013 After 3 months of simvastatin treatment apoB/Lp-PLA2 and apoB/Lp-PLA2- levels were reduced by 52% and 33%, respectively. Simvastatin 18-29 apolipoprotein B Homo sapiens 40-44 24092915-9 2013 After 3 months of simvastatin treatment apoB/Lp-PLA2 and apoB/Lp-PLA2- levels were reduced by 52% and 33%, respectively. Simvastatin 18-29 apolipoprotein B Homo sapiens 57-61 23880197-0 2013 Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. Simvastatin 48-59 apolipoprotein B Homo sapiens 84-100 23866306-5 2013 In non-obese subjects (n = 342), percent changes in LDL-C, total cholesterol, non-HDL-C, Apo B and Apo A-I were greater with ezetimibe/simvastatin vs doubling the baseline statin dose or switching to rosuvastatin; and treatment with ezetimibe/simvastatin resulted in greater changes in triglycerides vs rosuvastatin and HDL-C vs doubling the baseline statin dose. Simvastatin 135-146 apolipoprotein B Homo sapiens 89-94 23866306-7 2013 CONCLUSIONS: Regardless of baseline obesity status, switching to ezetimibe/simvastatin was more effective at reducing LDL-C, total cholesterol, non-HDL-C, and Apo B vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg. Simvastatin 75-86 apolipoprotein B Homo sapiens 159-164 23100282-3 2013 METHODS AND RESULTS: A genome-wide study of the LDL-C and apolipoprotein B (ApoB) response to 40 mg simvastatin daily was performed in 3895 participants in the Heart Protection Study, and the nine strongest associations were tested in 14 810 additional participants. Simvastatin 100-111 apolipoprotein B Homo sapiens 58-74 23100282-3 2013 METHODS AND RESULTS: A genome-wide study of the LDL-C and apolipoprotein B (ApoB) response to 40 mg simvastatin daily was performed in 3895 participants in the Heart Protection Study, and the nine strongest associations were tested in 14 810 additional participants. Simvastatin 100-111 apolipoprotein B Homo sapiens 76-80 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Simvastatin 47-58 apolipoprotein B Homo sapiens 110-126 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Simvastatin 38-49 apolipoprotein B Homo sapiens 108-113 19660610-0 2009 Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Simvastatin 125-136 apolipoprotein B Homo sapiens 101-117 20461472-0 2010 Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia. Simvastatin 13-24 apolipoprotein B Homo sapiens 28-36 20461472-3 2010 The objective of the study was to examine the influence of simvastatin on the secretion of apoB-100-containing lipoproteins in fasting non-obese subjects. Simvastatin 59-70 apolipoprotein B Homo sapiens 91-99 20142117-7 2010 Simvastatin also reduced the concentration of apolipoprotein B (125 to 93 mg/dL, p < 0.001). Simvastatin 0-11 apolipoprotein B Homo sapiens 46-62 20529243-10 2010 CONCLUSION: Expected synergistic lowering effects of a simvastatin and ezetimibe combination on LDL-cholesterol, apolipoprotein B and triglycerides levels were confirmed in subjects with early disturbances of glucose metabolism. Simvastatin 55-66 apolipoprotein B Homo sapiens 113-129 19660610-4 2009 Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. Simvastatin 0-11 apolipoprotein B Homo sapiens 118-122 19660610-4 2009 Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. Simvastatin 0-11 apolipoprotein B Homo sapiens 154-158 19660610-4 2009 Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. Simvastatin 33-44 apolipoprotein B Homo sapiens 118-122 19660610-4 2009 Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. Simvastatin 33-44 apolipoprotein B Homo sapiens 154-158 19660610-2 2009 The present analysis of the previously reported Simvastatin plus Fenofibrate for Combined Hyperlipidemia (SAFARI) trial assessed the associations of non-HDL cholesterol and LDL cholesterol with ApoB levels in patients with combined hyperlipidemia treated with combination simvastatin (20 mg) and fenofibrate (160 mg) or simvastatin monotherapy (20 mg). Simvastatin 48-59 apolipoprotein B Homo sapiens 194-198 19332196-8 2009 CONCLUSIONS: We demonstrate that full-dose niacin/moderate-dose simvastatin combination has sustained benefits on atherogenic apoB lipoproteins, at least comparable to high-dose simvastatin, while also raising HDL-cholesterol. Simvastatin 64-75 apolipoprotein B Homo sapiens 126-130 19327776-11 2009 The reduction in risk by intensive lipid-lowering treatment as compared to usual-dose simvastatin was well predicted by the difference in apoB/apoA-1 on-treatment levels. Simvastatin 86-97 apolipoprotein B Homo sapiens 138-142 19539078-6 2009 Significantly greater improvements in the levels of LDL cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B, and lipid/lipoprotein ratios resulted with ezetimibe/simvastatin compared with atorvastatin at all specified dose comparisons (p <0.001). Simvastatin 182-193 apolipoprotein B Homo sapiens 111-127 19618992-6 2009 CONCLUSIONS: The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100. Simvastatin 51-62 apolipoprotein B Homo sapiens 215-223 19305020-0 2009 Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. Simvastatin 25-36 apolipoprotein B Homo sapiens 40-56 19305020-7 2009 Our results indicate that treatment with simvastatin plus ezetimibe is effective in reducing plasma TRL apoB-48 levels and that this effect is most likely mediated by a reduction in the intestinal secretion of TRL apoB-48. Simvastatin 41-52 apolipoprotein B Homo sapiens 104-111 19305020-7 2009 Our results indicate that treatment with simvastatin plus ezetimibe is effective in reducing plasma TRL apoB-48 levels and that this effect is most likely mediated by a reduction in the intestinal secretion of TRL apoB-48. Simvastatin 41-52 apolipoprotein B Homo sapiens 214-221 18669979-5 2008 Whereas fenofibrate reduced cholesterol mass within VLDL and IDL, and shifted cholesterol from dense LDL subfractions into the more buoyant subfractions and HDL, ezetimibe/simvastatin reduced cholesterol mass within all apolipoprotein B-containing particles without significantly shifting the LDL particle distribution profile. Simvastatin 172-183 apolipoprotein B Homo sapiens 220-236 18957124-10 2008 Decreases in total cholesterol, LDL and apoB were greater with simvastatin. Simvastatin 63-74 apolipoprotein B Homo sapiens 40-44 17109866-3 2007 Simvastatin effectively lowered plasma LDL-C and apoB levels, but did not change plasma HDL levels and HDL-related biomarkers, except for a small, significant increase in the capacity of plasma to promote SR-BI mediated cholesterol efflux. Simvastatin 0-11 apolipoprotein B Homo sapiens 49-53 17318708-9 2007 These results show that children and adolescents with hypercholesterolemia present endothelial dysfunction, and simvastatin, in addition to significantly reducing TC, LDL-C, and apo B concentrations, restores endothelial function with 1-month treatment. Simvastatin 112-123 apolipoprotein B Homo sapiens 178-183